WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This trial is a single-center, open-label designed investigator-initiated clinical study
(IIT) to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of WTX212A
injection WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in patients with
advanced lung cancer
Phase:
Early Phase 1
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University